“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Attorney’s Legal Mal Suit Against NLJ 500 Firms Reinstated by Ill. Appellate Court
The appellate panel said the doctrine of unclean hands does